Compass Therapeutics Reports New PD-1 Cleavage Mechanism for CTX-10726 in Preclinical Studies

PUBT · 2d ago
Compass Therapeutics Reports New PD-1 Cleavage Mechanism for CTX-10726 in Preclinical Studies
  • Compass Therapeutics will present preclinical CTX-10726 findings at the Society for Immunotherapy of Cancer annual meeting on November 7, 2026.
  • The bispecific antibody removed PD-1 receptors from T cells only when VEGF-A was present, suggesting targeted activity in the tumor microenvironment.
  • Combining CTX-10726 with CTX-471 inhibited tumor growth more than either treatment alone in checkpoint inhibitor-resistant mouse models.
  • An ongoing Phase 1 dose-escalation trial is enrolling patients with advanced solid tumors whose standard treatments, including checkpoint inhibitors, have failed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060900PRIMZONEFULLFEED9871752) on November 06, 2026, and is solely responsible for the information contained therein.